Epidemiology of Cefotaxime-Hydrolysing β-Lactamase-Producing Escherichia coli in Children with Diarrhoea Reported Globally between 2012 and 2022
- PMID: 38257997
- PMCID: PMC10820611
- DOI: 10.3390/microorganisms12010171
Epidemiology of Cefotaxime-Hydrolysing β-Lactamase-Producing Escherichia coli in Children with Diarrhoea Reported Globally between 2012 and 2022
Abstract
The global spread of cefotaxime-hydrolysing β-lactamase (CTX-M)-producing Escherichia coli (E. coli) and its associated impact on paediatric diarrhoeal treatment and management has become a public health concern. This review assessed surveillance studies on CTX-M-producing E. coli associated with diarrhoea in children published between 2012 and 2022 globally. A total of thirty-eight studies were included for data analysis, categorised into continental regions, and tabulated. The majority (68%) of studies were conducted in Asian countries while few studies were conducted in Europe (11%) and Africa (18%), respectively. On the African continent, the majority (11%) of studies were conducted in Northern Africa while no studies were reported in East Africa. On the American continent, 3% of the studies were reported from South America. The studies included were classified into diarrheagenic E. coli (74%; 28/38) and faecal carriage (26%; 10/38). Of all the E. coli pathotypes associated with CTX-M production, EPEC was frequently reported. The prevalence of CTX-M-producing E. coli including the CTX-M-15-producing variants ranged between 1% and 94%. About 37% of the studies generalised the report as blaCTX-M-positive E. coli. The use of sequencing in characterising the CTX-M-producing E. coli was reported in only 32% of all the studies. This review provides information on the epidemiology of CTX-M-15-producing E. coli in paediatric diarrhoea and the extent to which surveillance is being performed. This is relevant in informing clinical practice for the management of diarrhoea as well as the design of future surveillance studies.
Keywords: CTX-M-producing E. coli; Escherichia coli; children; diarrhoea.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Molecular Epidemiology of Extended-Spectrum β-Lactamase-Producing Escherichia coli Pathotypes in Diarrheal Children from Low Socioeconomic Status Communities in Bihar, India: Emergence of the CTX-M Type.Infect Dis (Auckl). 2017 Nov 6;10:1178633617739018. doi: 10.1177/1178633617739018. eCollection 2017. Infect Dis (Auckl). 2017. PMID: 29151781 Free PMC article.
-
Nasal carriage of CTX-M-55-producing Escherichia coli ST8369 in a healthy cohort in the city of Yangzhou, China.Front Cell Infect Microbiol. 2022 Aug 3;12:970940. doi: 10.3389/fcimb.2022.970940. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35992163 Free PMC article.
-
Antimicrobial Resistance Genes and Diversity of Clones among Faecal ESBL-Producing Escherichia coli Isolated from Healthy and Sick Dogs Living in Portugal.Antibiotics (Basel). 2021 Aug 20;10(8):1013. doi: 10.3390/antibiotics10081013. Antibiotics (Basel). 2021. PMID: 34439063 Free PMC article.
-
Antibiotic resistance in Escherichia coli in husbandry animals: the African perspective.Lett Appl Microbiol. 2017 May;64(5):318-334. doi: 10.1111/lam.12724. Lett Appl Microbiol. 2017. PMID: 28208218 Review.
-
Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.Drugs. 2019 Sep;79(14):1529-1541. doi: 10.1007/s40265-019-01180-3. Drugs. 2019. PMID: 31407238 Review.
Cited by
-
Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.BMC Pharmacol Toxicol. 2025 Jul 1;26(1):129. doi: 10.1186/s40360-025-00960-w. BMC Pharmacol Toxicol. 2025. PMID: 40598696 Free PMC article.
-
A Review of Medicinal Plants Used in the Management of Microbial Infections in Angola.Plants (Basel). 2024 Oct 26;13(21):2991. doi: 10.3390/plants13212991. Plants (Basel). 2024. PMID: 39519911 Free PMC article. Review.
-
Dimetridazole potentiates cefotaxime against multidrug-resistant E. coli via membrane disruption and fatty acid composition.Sci Rep. 2025 Jul 1;15(1):21171. doi: 10.1038/s41598-025-07751-7. Sci Rep. 2025. PMID: 40594620 Free PMC article.
References
-
- Troeger C., Blacker B.F., Khalil I.A., Rao P.C., Cao S., Zimsen S.R., Albertson S.B., Stanaway J.D., Deshpande A., Abebe Z., et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: Asystematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 2018;18:1211–1228. doi: 10.1016/S1473-3099(18)30362-1. - DOI - PMC - PubMed
-
- Hamad W.F. Genotypic and phenotypic study of E. coli isolated from children suffering from severe diarrhea with some antibiotic resistant gene. World J. Adv. Res. Rev. 2022;15:683–693. doi: 10.30574/wjarr.2022.15.1.0758. - DOI
Publication types
LinkOut - more resources
Full Text Sources